Relistor® (methylnaltrexone bromide) – New formulation approval
July 19, 2016 – Valeant and Progenics announced the FDA approval of Relistor (methylnaltrexone bromide) tablets, for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain (NCP).
Download PDF
